Scientific Publications

Search by Keyword(s)
Found 7 results

Filters: Author is Gray, NS  [Clear All Filters]

Search Results

  • Showing 1-7 of 7 Results
2014
Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma.Moore, NF, Azarova AM, Bhatnagar N., Ross KN, Drake LE, Frumm S., Liu QS, Christie AL, Sanda T., Chesler L., Kung AL, Gray NS, Stegmaier K., and George RE Oncotarget, 2014/08/19, (2014) Read More / View Supplemental Materials
Abstract
Small-molecule screening identifies inhibition of salt-inducible kinases as a therapeutic strategy to enhance immunoregulatory functions of dendritic cells.Sundberg, TB, Choi HG, Song JH, Russell CN, Hussain MM, Graham DB, Khor B., Gagnon J., O'Connell DJ, Narayan K., Dančík V., Perez JR, Reinecker HC, Gray NS, Schreiber SL, Xavier RJ, and Shamji AF Proceedings of the National Academy of Sciences of the United States of America, 2014/08/11, (2014) Read More / View Supplemental Materials
Abstract
Targeting transcription regulation in cancer with a covalent CDK7 inhibitor.Kwiatkowski, N., Zhang T., Rahl PB, Abraham BJ, Reddy J., Ficarro SB, Dastur A., Amzallag A., Ramaswamy S., Tesar B., Jenkins CE, Hannett NM, McMillin D., Sanda T., Sim T., Kim ND, Look T., Mitsiades CS, Weng AP, Brown JR, et al. Nature, 2014/06/22, (2014) Read More / View Supplemental Materials
Abstract
Ligand-associated ERBB2/3 activation confers acquired resistance to FGFR inhibition in FGFR3-dependent cancer cells.Wang, J., Mikse O., Liao RG, Li Y., Tan L., Janne PA, Gray NS, Wong KK, and Hammerman PS Oncogene, 2014/06/09, (2014) Read More / View Supplemental Materials
Abstract
2013
Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma.Liao, RG, Jung J., Tchaicha JH, Wilkerson MD, Sivachenko A., Beauchamp EM, Pugh TJ, Pedamallu CS, Hayes DN, Gray NS, Getz G., Wong KK, Meyerson M., and Hammerman PS Cancer research, 2013/06/20, (2013) Read More / View Supplemental Materials
Abstract
2011
Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer.Dutt, A., Ramos AH, Hammerman PS, Mermel C., Cho J., Sharifnia T., Chande A., Tanaka KE, Stransky N., Greulich H., Gray NS, and Meyerson M. PloS one, 2011/01/01, Volume 6, Issue 6, p.e20351, (2011) Read More / View Supplemental Materials
Abstract
2008
Activating mutations in ALK provide a therapeutic target in neuroblastoma.George, RE, Sanda T., Hanna M., Fröhling S., Luther W 2nd, Zhang J., Ahn Y., Zhou W., London WB, McGrady P., Xue L., Zozulya S., Gregor VE, Webb TR, Gray NS, Gilliland DG, Diller L., Greulich H., Morris SW, Meyerson M., et al. Nature, 2008/10/16, Volume 455, Issue 7215, p.975-8, (2008) Read More / View Supplemental Materials
Abstract
  • Showing 1-7 of 7 Results